Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Stuttgart - Delayed Quote EUR

Takeda Pharmaceutical Co Ltd (TKD.SG)

Compare
26.28
-0.22
(-0.83%)
At close: 8:17:48 AM GMT+1
Currency in JPY All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
4,579,021,000
4,263,762,000
4,027,478,000
3,569,006,000
3,197,812,000
Cost of Revenue
1,580,640,000
1,426,678,000
1,244,072,000
1,106,846,000
994,308,000
Gross Profit
2,998,381,000
2,837,084,000
2,783,406,000
2,462,160,000
2,203,504,000
Operating Expense
2,484,053,000
2,516,131,000
2,228,519,000
1,916,117,000
1,785,951,000
Operating Income
514,328,000
320,953,000
554,887,000
546,043,000
417,553,000
Net Non Operating Interest Income Expense
-145,837,000
-140,463,000
-123,385,000
-123,477,000
-138,153,000
Other Income Expense
-133,627,000
-127,697,000
-56,411,000
-119,997,000
86,835,000
Pretax Income
234,861,000
52,791,000
375,090,000
302,571,000
366,235,000
Tax Provision
26,614,000
-91,406,000
58,052,000
72,405,000
-9,936,000
Net Income Common Stockholders
208,065,000
144,067,000
317,017,000
230,059,000
376,005,000
Diluted NI Available to Com Stockholders
208,065,000
144,067,000
317,017,000
230,059,000
376,005,000
Basic EPS
131.70
92.09
204.29
147.14
240.72
Diluted EPS
129.68
91.16
201.94
145.87
238.96
Basic Average Shares
1,552,772.33
1,564,450
1,551,809
1,563,501
1,562,006
Diluted Average Shares
1,598,496.43
1,580,343
1,569,872
1,577,169
1,573,537
Total Operating Income as Reported
407,449,000
214,075,000
490,505,000
460,844,000
509,269,000
Total Expenses
4,064,693,000
3,942,809,000
3,472,591,000
3,022,963,000
2,780,259,000
Net Income from Continuing & Discontinued Operation
208,065,000
144,067,000
317,017,000
230,059,000
376,005,000
Normalized Income
327,031,111.83
247,109,560
376,349,737.44
316,103,388.23
315,811,605.80
Interest Income
-7,003,000
11,293,000
5,508,000
4,591,000
1,781,000
Interest Expense
106,613,000
119,535,000
116,973,000
122,432,000
130,806,000
Net Interest Income
-145,837,000
-140,463,000
-123,385,000
-123,477,000
-138,153,000
EBIT
341,474,000
172,326,000
492,063,000
425,003,000
497,041,000
EBITDA
1,099,845,000
900,328,000
1,156,463,000
1,008,154,000
1,056,712,000
Reconciled Cost of Revenue
1,407,541,000
1,350,793,000
1,122,115,000
996,610,000
856,501,000
Reconciled Depreciation
758,371,000
728,002,000
664,400,000
583,151,000
559,671,000
Net Income from Continuing Operation Net Minority Interest
208,065,000
144,067,000
317,017,000
230,059,000
376,005,000
Total Unusual Items Excluding Goodwill
-134,170,000
-134,170,000
-70,197,000
-113,112,000
86,759,000
Total Unusual Items
-134,170,000
-134,170,000
-70,197,000
-113,112,000
86,759,000
Normalized EBITDA
1,234,015,000
1,034,498,000
1,226,660,000
1,121,266,000
969,953,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-15,203,888.17
-31,127,440
-10,864,262.56
-27,067,611.77
26,565,605.80
3/31/2021 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade